Literature DB >> 9577374

Clinical and histological associations of cagA and vacA genotypes in Helicobacter pylori gastritis.

V J Warburton1, S Everett, N P Mapstone, A T Axon, P Hawkey, M F Dixon.   

Abstract

AIMS: To determine the relation among the cytotoxin associated gene (cagA) and vacuolating cytotoxin gene (vacA) status of Helicobacter pylori isolates, the associated clinical diseases, and the severity and pattern of chronic gastritis.
METHODS: Helicobacter pylori was cultured from gastric biopsies obtained from dyspeptic patients. DNA was extracted from the isolates and the cagA and vacA status determined by the polymerase chain reaction (PCR). The prevalence of the different cagA and vacA genotypes in three clinical groups, duodenal ulcer, gastric ulcer, and non-ulcer dyspepsia was compared. The histological features in sections from two antral and two corpus biopsies were graded by one blinded observer. The grades were compared with age and sex matched groups with different cagA and vacA genotypes, and with duodenal ulcers, or non-ulcer dyspepsia.
RESULTS: Isolates from 161 patients were included. One hundred and nine (68%) harboured a cagA+ strain and 143 (89%) harboured a vacA s1 strain. The prevalence of cagA+ strains in duodenal ulcer patients (94%) was highly significantly greater than in those with non-ulcer dyspepsia (56%). However, of the patients infected with a cagA+ strain, almost equal numbers had non-ulcer dyspepsia or peptic ulceration. Chronic inflammation, polymorph activity, surface epithelial degeneration, atrophy, and intestinal metaplasia were all significantly more severe in the cagA+ than in the cagA- group, whereas only corpus epithelial degeneration was significantly more severe in the vacA s1 group compared with the vacA s2 group. Patients infected with cagA+ strains were almost four times more likely to have antral intestinal metaplasia than cagA- patients. An antral predominant gastritis was present in duodenal ulcer patients compared with matched non-ulcer dyspepsia patients, but this was not attributable to cagA or vacA status.
CONCLUSIONS: Helicobacter pylori strains showing cagA positively and the vacA s1 genotype are associated with more severe gastritis but these virulence factors do not appear to determine the overall pattern. The pattern is closely linked to clinical disease. Therefore, it is likely that the nature of the disease complicating chronic infection is determined by host and environmental factors, while bacterial factors determine the magnitude of the risk of developing such disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9577374      PMCID: PMC500433          DOI: 10.1136/jcp.51.1.55

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  26 in total

1.  Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection.

Authors:  J Parsonnet; G D Friedman; N Orentreich; H Vogelman
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

Review 2.  Helicobacter pylori and peptic ulceration: histopathological aspects.

Authors:  M F Dixon
Journal:  J Gastroenterol Hepatol       Date:  1991 Mar-Apr       Impact factor: 4.029

3.  Profile of Helicobacter pylori cytotoxin derived from two areas of Japan with different prevalence of atrophic gastritis.

Authors:  S Ito; T Azuma; H Murakita; M Hirai; H Miyaji; Y Ito; Y Ohtaki; Y Yamazaki; M Kuriyama; Y Keida; Y Kohli
Journal:  Gut       Date:  1996-12       Impact factor: 23.059

4.  Direct polymerase chain reaction test for detection of Helicobacter pylori in humans and animals.

Authors:  S A Ho; J A Hoyle; F A Lewis; A D Secker; D Cross; N P Mapstone; M F Dixon; J I Wyatt; D S Tompkins; G R Taylor
Journal:  J Clin Microbiol       Date:  1991-11       Impact factor: 5.948

5.  Cytotoxin production by Campylobacter pylori strains isolated from patients with peptic ulcers and from patients with chronic gastritis only.

Authors:  N Figura; P Guglielmetti; A Rossolini; A Barberi; G Cusi; R A Musmanno; M Russi; S Quaranta
Journal:  J Clin Microbiol       Date:  1989-01       Impact factor: 5.948

6.  Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of Helicobacter pylori.

Authors:  J C Atherton; R M Peek; K T Tham; T L Cover; M J Blaser
Journal:  Gastroenterology       Date:  1997-01       Impact factor: 22.682

7.  Presence of the cagA gene in the majority of Helicobacter pylori strains is independent of whether the individual has duodenal ulcer or asymptomatic gastritis.

Authors:  M F Go; D Y Graham
Journal:  Helicobacter       Date:  1996-06       Impact factor: 5.753

8.  Cloning and expression of a high-molecular-mass major antigen of Helicobacter pylori: evidence of linkage to cytotoxin production.

Authors:  M K Tummuru; T L Cover; M J Blaser
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

Review 9.  Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention.

Authors:  P Correa
Journal:  Cancer Res       Date:  1992-12-15       Impact factor: 12.701

10.  Characterization of and human serologic response to proteins in Helicobacter pylori broth culture supernatants with vacuolizing cytotoxin activity.

Authors:  T L Cover; C P Dooley; M J Blaser
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

View more
  24 in total

1.  Increased expression of IL-10 and IL-12 (p40) mRNA in Helicobacter pylori infected gastric mucosa: relation to bacterial cag status and peptic ulceration.

Authors:  N Hida; T Shimoyama; P Neville; M F Dixon; A T Axon; T Shimoyama; J E Crabtree
Journal:  J Clin Pathol       Date:  1999-09       Impact factor: 3.411

2.  Regional differences on production of chemokines in gastric mucosa between Helicobacter pylori-positive duodenal ulcer and gastric ulcer.

Authors:  Y Sato; K Sugimura; T Mochizuki; T Honma; H Suriki; K Tashiro; K Ishizuka; R Narisawa; T Ichida; D H Van Thiel; H Asakura
Journal:  Dig Dis Sci       Date:  1999-12       Impact factor: 3.199

3.  Prevalence and genotypes of Helicobacter pylori in gastric biopsy specimens from patients with gastroduodenal pathologies in the Cukurova Region of Turkey.

Authors:  Togrul Nagiyev; Erkan Yula; Bahri Abayli; Fatih Koksal
Journal:  J Clin Microbiol       Date:  2009-10-21       Impact factor: 5.948

Review 4.  Are all helicobacters equal? Mechanisms of gastroduodenal pathology and their clinical implications.

Authors:  A T Axon
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

5.  Helicobacter pylori non-cytotoxic genotype enhances mucosal gastrin and mast cell tryptase.

Authors:  D Basso; F Navaglia; L Brigato; F Di Mario; M Rugge; M Plebani
Journal:  J Clin Pathol       Date:  1999-03       Impact factor: 3.411

6.  Consensus and variable region PCR analysis of Helicobacter pylori 3' region of cagA gene in isolates from individuals with or without peptic ulcer.

Authors:  C A Rota; J C Pereira-Lima; C Blaya; N B Nardi
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

7.  Helicobacter pylori in Dyspepsia - Antibiotic Sensitivity and Virulence Patterns.

Authors:  R N Misra; M Bhagat; N Ahmed
Journal:  Med J Armed Forces India       Date:  2011-07-21

8.  Association between vacA genotypes and the risk of duodenal ulcer: a meta-analysis.

Authors:  Bei-Bei Zhang; Yong Li; Xue-Qiang Liu; Pei-Jian Wang; Bo Yang; Dong-Lin Bian
Journal:  Mol Biol Rep       Date:  2014-07-26       Impact factor: 2.316

9.  Serum positive cagA in patients with non-ulcer dyspepsia and peptic ulcer disease from two centers in different regions of Turkey.

Authors:  Ender Serin; Uğur Yilmaz; Ganiye Künefeci; Birol Ozer; Yuksel Gümürdülü; Mustafa Güçlü; Fazilet Kayaselçuk; Sedat Boyacioğlu
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

Review 10.  Polymorphism in the Helicobacter pylori CagA and VacA toxins and disease.

Authors:  Dacie R Bridge; D Scott Merrell
Journal:  Gut Microbes       Date:  2013-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.